Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Combined Lesion Distribution Parameter Predicts Disease Progression in Multiple Sclerosis
Multiple Sclerosis
S26 - MS Imaging (1:48 PM-2:00 PM)
005

The dominant lesion type in progressive multiple sclerosis is a chronic lesion, and particularly chronic active lesions harboring a lesion border of activated microglia and macrophage cells have been associated with lesion growth and disability accumulation.

To investigate whether the frequency of TSPO-PET-identifiable chronic active lesions predicts later multiple sclerosis disease progression.

The innate immune cell activation was evaluated at baseline using PET-imaging with a TSPO-binding radioligand 11C-PK11195 in 82 multiple sclerosis patients. Conventional MRI and disability measurements using the Expanded Disability Status Scale were performed for patients at baseline and 5.0±1.7 years later (mean±SD). Chronic lesions were categorized into three categories: rim-active, inactive and overall-active, based on their PET-detectable innate immune cell activation patterns in the lesion core and in the 2-mm perilesional rim. Progressed and non-progressed patients were first compared using Wilcoxon rank-sum test and finally forward-type stepwise logistic regression was used to find the most important predictors of progression.

Twenty-one (26%) patients experienced disability progression during the follow-up. These patients had significantly higher absolute and volume proportions of rim-active lesions (P < 0.001 in both) and significantly lower absolute and volume proportions of inactive lesions (P < 0.001 and P = 0.007, respectively) compared to non-progressed patients. The results were similar in the patient group free of relapses (n = 60). In logistic regression the model with categorized variable ‘patients with proportion of rim-active lesions > 10% and proportion of inactive lesions ≤ 50% vs. others’, predicted disease progression both in the entire patient cohort (OR = 26.8, p < 0.001) and in the patient group free of relapses (OR = 34.8, p = 0.002).

The results show that in-vivo lesion phenotyping provides remarkable predictors for disease progression. This emphasizes the significance of chronic active lesions in disability accumulation in multiple sclerosis.
Authors/Disclosures
Eero Polvinen
PRESENTER
Mr. Polvinen has nothing to disclose.
No disclosure on file
Marjo Nylund (Turku University Hospital) Ms. Nylund has received research support from The Finnish MS Foundation. Ms. Nylund has received research support from Maire Taponen Foundation. Ms. Nylund has received research support from The Finnish Cultural Foundation.
Marcus Sucksdorff, MD (University of Turku) Dr. Sucksdorff has nothing to disclose.
Laura Airas, MD, PhD (Turku University Hospital) The institution of Dr. Airas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. The institution of Dr. Airas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.